MA53099A - Formes d'ivosidénib et compositions pharmaceutiques - Google Patents

Formes d'ivosidénib et compositions pharmaceutiques

Info

Publication number
MA53099A
MA53099A MA053099A MA53099A MA53099A MA 53099 A MA53099 A MA 53099A MA 053099 A MA053099 A MA 053099A MA 53099 A MA53099 A MA 53099A MA 53099 A MA53099 A MA 53099A
Authority
MA
Morocco
Prior art keywords
ivosidenib
forms
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
MA053099A
Other languages
English (en)
Inventor
Chong-Hui Gu
Jacob Paul Sizemore
Shijie Zhang
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MA53099A publication Critical patent/MA53099A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053099A 2018-07-06 2019-07-02 Formes d'ivosidénib et compositions pharmaceutiques MA53099A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06

Publications (1)

Publication Number Publication Date
MA53099A true MA53099A (fr) 2021-05-12

Family

ID=69059942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053099A MA53099A (fr) 2018-07-06 2019-07-02 Formes d'ivosidénib et compositions pharmaceutiques

Country Status (17)

Country Link
US (1) US20210323944A1 (fr)
EP (1) EP3817744A4 (fr)
JP (1) JP2021529805A (fr)
KR (1) KR20210029775A (fr)
CN (1) CN112367995A (fr)
AU (1) AU2019299352A1 (fr)
BR (1) BR112021000156A2 (fr)
CA (1) CA3103498A1 (fr)
EA (1) EA202190217A1 (fr)
IL (1) IL279877A (fr)
MA (1) MA53099A (fr)
MX (2) MX2021000068A (fr)
PH (1) PH12021550017A1 (fr)
SG (1) SG11202012763TA (fr)
TW (1) TW202019419A (fr)
WO (1) WO2020010058A1 (fr)
ZA (1) ZA202008034B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4010331B1 (fr) * 2019-08-08 2023-10-04 Les Laboratoires Servier Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346801B (es) 2009-03-13 2017-03-31 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular.
EP2491145B1 (fr) 2009-10-21 2016-03-09 Agios Pharmaceuticals, Inc. Procédés et compositions pour des troubles relatifs à la prolifération cellulaire
CN103459394B (zh) * 2011-04-08 2016-04-27 辉瑞大药厂 结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
JP6524119B2 (ja) * 2014-03-14 2019-06-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物の医薬組成物
US9968595B2 (en) * 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
ES2897959T3 (es) * 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
MX2018010261A (es) * 2016-02-26 2019-02-11 Agios Pharmaceuticals Inc Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
WO2019104318A1 (fr) * 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Formes à l'état solide d'ivosidénib

Also Published As

Publication number Publication date
CA3103498A1 (fr) 2020-01-09
IL279877A (en) 2021-03-01
EA202190217A1 (ru) 2021-04-16
TW202019419A (zh) 2020-06-01
PH12021550017A1 (en) 2021-09-13
EP3817744A4 (fr) 2022-07-13
ZA202008034B (en) 2021-10-27
JP2021529805A (ja) 2021-11-04
WO2020010058A1 (fr) 2020-01-09
BR112021000156A2 (pt) 2021-04-06
CN112367995A (zh) 2021-02-12
AU2019299352A1 (en) 2021-01-07
US20210323944A1 (en) 2021-10-21
MX2021000068A (es) 2021-03-25
MX2023011687A (es) 2023-10-19
EP3817744A1 (fr) 2021-05-12
KR20210029775A (ko) 2021-03-16
SG11202012763TA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
MA55206A (fr) Polyribonucléotides circulaires et compositions pharmaceutiques associées
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
EP3706741A4 (fr) Composition pharmaceutique et utilisation associée
MA55015A (fr) Formulations pharmaceutiques
MA54052A (fr) Formulation d'anticorps
MA54139A (fr) Formulation d'anticorps
MA49837A (fr) Compositions pharmaceutiques
EP3894408A4 (fr) Triazolopyridin-3-ones ou leurs sels et compositions pharmaceutiques les comprenant
ES2850277R1 (es) Composiciones de administración farmacéutica y usos de las mismas
MA55033A (fr) Formulation d'anticorps thérapeutique
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
MA53099A (fr) Formes d'ivosidénib et compositions pharmaceutiques
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
MA53368A (fr) Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
MA54095A (fr) Formulations pharmaceutiques aqueuses
MA54222A (fr) Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées